Skip to main content
. Author manuscript; available in PMC: 2015 Jan 26.
Published in final edited form as: Breast Cancer Res Treat. 2011 Jul 19;130(3):975–980. doi: 10.1007/s10549-011-1666-0

Table 2.

Breast cancer-specific and all-cause mortality by parity status and stratified by histologic subtypea

All histologies
Ductal subtype
Lobular subtype
Mixed Ductal-lobular subtype
Cases Events HR (95%CI) Cases Events HR (95%CI) Cases Events HR (95%CI) Cases Events HR (95%CI)
Parity Breast cancer-specific mortality
Nulliparous 3046 445 1 2463 366 1 235 42 1 108 10 1
1 2502 401 1.06 (0.93 – 1.22) 2007 341 1.08 (0.93 – 1.25) 192 24 0.82 (0.48 – 1.40) 100 14 2.77 (1.02 – 7.50)
2 6469 820 0.91 (0.81 – 1.02) 5135 679 0.89 (0.78 – 1.01) 550 76 0.98 (0.65 – 1.48) 267 25 1.31 (0.54 – 3.18)
3 4815 628 0.92 (0.81 – 1.04) 3787 515 0.92 (0.80 – 1.05) 462 65 0.81 (0.54 – 1.24) 199 19 1.70 (0.65 – 4.40)
4 2790 371 0.86 (0.74 – 0.98) 2198 298 0.83 (0.71 – 0.97) 265 41 0.89 (0.56 – 1.41) 85 11 1.01 (0.33 – 3.09)
5+ 2660 385 0.86 (0.74 – 0.99) 2088 311 0.85 (0.73 – 1.00) 249 37 0.70 (0.43 – 1.14) 90 9 1.93 (0.64 – 5.87)
PTrend 0.002 0.002 0.18 0.85
Parity All-cause mortality
Nulliparous 3046 910 1 2463 737 1 235 80 1 108 22 1
1 2502 798 1.01 (0.92 – 1.11) 2007 659 1.03 (0.92 – 1.14) 192 58 0.95 (0.66 – 1.35) 100 27 1.31 (0.67 – 2.55)
2 6469 1634 0.91 (0.84 – 0.99) 5135 1325 0.90 (0.83 – 0.99) 550 141 0.91 (0.68 – 1.22) 267 43 0.76 (0.42 – 1.37)
3 4815 1281 0.90 (0.82 – 0.98) 3787 1031 0.90 (0.82 – 0.99) 462 129 0.77 (0.57 – 1.03) 199 35 0.84 (0.45 – 1.57)
4 2790 838 0.86 (0.78 – 0.95) 2198 670 0.86 (0.77 – 0.96) 265 87 0.80 (0.58 – 1.09) 85 18 0.52 (0.25 – 1.09)
5+ 2660 941 0.92 (0.84 – 1.01) 2088 753 0.92 (0.83 – 1. 02) 249 85 0.83 (0.60 – 1.14) 90 21 0.84 (0.42 – 1.68)
PTrend 0.002 0.004 0.09 0.12

HR indicates hazard rate ratio; CI confidence interval

a

Proportional hazards models were stratified by state of residence, year of interview and age at diagnosis and adjusted for menopausal status, BMI, hormone replacement therapy use, smoking status, mammography, time from date of diagnosis to interview and stage of disease at diagnosis.